Regeneron Pharmaceuticals Inc. (REGN)

286.85
NASDAQ : Health Technology
Prev Close 295.02
Day Low/High 285.55 / 296.26
52 Wk Low/High 287.66 / 442.00
Avg Volume 755.70K
Exchange NASDAQ
Shares Outstanding 107.98M
Market Cap 32.42B
EPS 22.60
P/E Ratio 16.38
Div & Yield N.A. (N.A)

Latest News

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe

TARRYTOWN, N.Y.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Will Gilead Sciences Stock Really Rally 33% From Here?

Will Gilead Sciences Stock Really Rally 33% From Here?

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

Real Money Post Industrial Average Enjoyed a Stellar First Half of 2019

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

FDA Approves Dupixent® (dupilumab) For Chronic Rhinosinusitis With Nasal Polyposis

* First biologic medicine for adults with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP)

2 Well-Known Stocks You Should Consider Shorting This Week

2 Well-Known Stocks You Should Consider Shorting This Week

These bearish bets are showing both technical and quantitative deterioration.

A Biotech Biggie, a Watchmaker and Other Stocks That Look Good Short

REGN, NOMD, LMNR, MOV and HTHT all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: SCM, UFCS Downgrades: GCO, GIII, JE, KR, MLAB, OCC, PK, REGN, TAIT, WMK Initiations: HMI, PVTL, SMAR Read on to get TheStreet Quant Ratings' detailed report:

A Six-Pack of Biotech Best Bets

A Six-Pack of Biotech Best Bets

Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.

Regeneron Announces Upcoming Investor Conference Presentation

Regeneron Announces Upcoming Investor Conference Presentation

TARRYTOWN, N.Y.

FDA Approves EYLEA® (aflibercept) Injection For Diabetic Retinopathy

FDA Approves EYLEA® (aflibercept) Injection For Diabetic Retinopathy

- EYLEA improves diabetic retinopathy and prevents worsening disease that can lead to blindness

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron Stock Could Fall 13% to 52-Week Lows

Regeneron stock is under pressure after missing on earnings and revenue expectations. Are new lows on tap?

Regeneron Declines on First-Quarter Earnings Miss

Regeneron Declines on First-Quarter Earnings Miss

The company misses big on analysts bottom-line expectations.

TheStreet Quant Rating: C+ (Hold)